ArticleArchives of dermatological research2025
A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oral JΑΚ Inhibitors in Vitiligo Treatment.Dermatology and therapy · 2026Review
- JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral Janus Kinase (JAK) inhibitors represent a significant advancement in the treatment of vitiligo; however, large-scale clinical data on their optimal treatment duration and efficacy remain limited. This study aimed to evaluate the efficacy and safety of the oral JAK inhibitor tofacitinib in patients with active vitiligo over a 3-month period. A retrospective analysis was conducted on patients diagnosed with active vitiligo between June 2023 and January 2024 who received oral tofacitinib for at least 3 months. Data were extracted from patient records. Vitiligo activity was assessed based on the Vitiligo Disease Activity (VIDA) score in combination with specific clinical manifestations, while treatment efficacy was evaluated based on the Vitiligo Area Severity Index (VASI). Safety data were reviewed retrospectively throughout the treatment period. A total of 137 patients were included in the study. The VIDA score improved from 2.75 ± 1.15 at baseline to 1.63 ± 0.66 at treatment discontinuation, with 59.1% (81/137) of patients achieving disease stabilization. The baseline VASI score was 3.79 (1.54-4.0), which decreased to 2.68 (1.0-2.92), reflecting an overall 29.3% improvement. After 3 months of treatment, 98 patients continued to take tofacitinib. Patients who received treatment for 6-9 months demonstrated significantly greater repigmentation (42.27% improvement) compared to those treated for less than 6 months (P < 0.05). No significant differences in efficacy were observed between non-segmental and segmental vitiligo. Mild adverse reactions were reported in 13.8% of patients, primarily including gastrointestinal discomfort, acne, elevated liver enzymes, and palpitations, with no severe adverse events recorded. In conclusion, oral tofacitinib administered for 3 months effectively stabilized vitiligo progression, while treatment extending to 6-9 months results in greater repigmentation and maintained a favorable safety profile. Further long-term controlled studies are warranted to validate these findings and optimize treatment strategies. Trial registration: http://www.chictr.org.cn . identifier: ChiCTR2400092326.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.